| 1 | DKK1/PDGFA ratio | GCST90314475 | 83.24 |
| 2 | Platelet crit (UKB data field 30090) | GCST90468096 | 77.80 |
| 3 | Mosaic chromosomal alteration of the Y chromosome | GCST90165289 | 75.23 |
| 4 | FLT3LG levels | GCST90469250 | 73.73 |
| 5 | EDAR levels | GCST90469068 | 69.19 |
| 6 | Plateletcrit | GCST90002400 | 67.48 |
| 7 | MMP1/SERPINB6 ratio | GCST90315462 | 64.05 |
| 8 | Mean corpuscular volume | Blood count | UKBB00000449 | 63.29 |
| 9 | Platelet crit | Blood count | UKBB00000647 | 63.15 |
| 10 | EDAR/SDC4 ratio | GCST90314585 | 62.06 |
| 11 | Mean reticulocyte volume | GCST90002396 | 61.33 |
| 12 | Anterior diffusion tensor imaging along the perivascular space index | GCST90455543 | 61.16 |
| 13 | Mean reticulocyte volume (UKB data field 30260) | GCST90468088 | 60.65 |
| 14 | Platelet count during first trimester of pregnancy | GCST90302224 | 57.46 |
| 15 | Mean corpuscular volume | GCST90002392 | 57.26 |
| 16 | CD244/EDAR ratio | GCST90313764 | 57.25 |
| 17 | Mean corpuscular haemoglobin | Blood count | UKBB00000447 | 56.62 |
| 18 | EDAR/TREML2 ratio | GCST90314592 | 56.43 |
| 19 | Mean reticulocyte volume | Blood count | UKBB00000451 | 55.80 |
| 20 | Platelet count | Blood count | UKBB00000646 | 55.32 |
| 21 | MMP1 levels | GCST90469919 | 54.97 |
| 22 | Mean corpuscular volume (UKB data field 30040) | GCST90468086 | 53.81 |
| 23 | Mean corpuscular haemoglobin (UKB data field 30050) | GCST90468084 | 53.34 |
| 24 | Mean corpuscular volume | GCST90018746 | 52.48 |
| 25 | Platelet count | GCST90002402 | 50.03 |
| 26 | Mean corpuscular hemoglobin | GCST90002390 | 47.97 |
| 27 | mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed) | GCST90475450 | 47.38 |
| 28 | Platelet count | GCST90278640 | 46.99 |
| 29 | Platelet count (UKB data field 30080) | GCST90468095 | 46.91 |
| 30 | platelet count (maximum, inv-norm transformed) | GCST90476296 | 46.73 |
| 31 | CRISP3 levels | GCST90468866 | 46.70 |
| 32 | EDAR/TNFSF12 ratio | GCST90314591 | 46.60 |
| 33 | mean corpuscular hemoglobin (MCH, mean, inv-norm transformed) | GCST90475446 | 45.29 |
| 34 | Mean corpuscular volume | GCST90002335 | 45.24 |
| 35 | Mean corpuscular hemoglobin | GCST90018744 | 45.09 |
| 36 | Blood cell traits latent factor 8 (white cell) | GCST90559250 | 44.64 |
| 37 | Mean sphered cell volume (UKB data field 30270) | GCST90468089 | 44.62 |
| 38 | Mean sphered cell volume | Blood count | UKBB00000452 | 44.38 |
| 39 | Mean spheric corpuscular volume | GCST90002397 | 44.05 |
| 40 | Mean corpuscular volume | GCST004602 | 43.91 |
| 41 | mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed) | GCST90475442 | 43.59 |
| 42 | White blood cell count (basophil) | GCST004618 | 43.47 |
| 43 | OSCAR levels | GCST90470131 | 42.63 |
| 44 | CCN2 levels | GCST90468588 | 42.16 |
| 45 | Drive faster than motorway speed limit | Physical activity | UKBB00000194 | 41.82 |
| 46 | Basophil count | GCST90002293 | 41.80 |
| 47 | Basophil percentage of white cells | GCST004631 | 41.64 |
| 48 | CPXM1/VEGFC ratio | GCST90314223 | 41.63 |
| 49 | white blood cell count (WBC, maximum, inv-norm transformed) | GCST90476451 | 41.32 |
| 50 | Total diffusion tensor imaging along the perivascular space index | GCST90455546 | 40.97 |
| 51 | mean corpuscular volume (MCV, maximum, inv-norm transformed) | GCST90475466 | 40.33 |
| 52 | SEMA4D/TREML2 ratio | GCST90315823 | 40.29 |
| 53 | MMP1/MMP3 ratio | GCST90315461 | 40.09 |
| 54 | mean corpuscular volume (MCV, mean, inv-norm transformed) | GCST90475470 | 39.91 |
| 55 | Mean corpuscular hemoglobin | GCST004630 | 39.88 |
| 56 | platelet count (mean, inv-norm transformed) | GCST90476299 | 39.79 |
| 57 | IDP dMRI ProbtrackX L1 slf r | GCST90004268 | 39.52 |
| 58 | Platelet count during second trimester of pregnancy | GCST90302225 | 39.28 |
| 59 | TNFRSF10C levels | GCST90470901 | 39.09 |
| 60 | SDC4 levels | GCST90470559 | 38.97 |
| 61 | mean corpuscular volume (MCV, minimum, inv-norm transformed) | GCST90475474 | 37.94 |
| 62 | PDGFA/VEGFC ratio | GCST90315622 | 37.84 |
| 63 | Non-cancer illness code, self-reported - type 2 diabetes | Medical conditions | UKBB00000522 | 37.79 |
| 64 | CPXM1/SPARC ratio | GCST90314222 | 37.38 |
| 65 | Platelet distribution width (UKB data field 30110) | GCST90468097 | 37.15 |
| 66 | DKK1/SDC4 ratio | GCST90314479 | 37.09 |
| 67 | SDC4/SERPINE1 ratio | GCST90315819 | 36.63 |
| 68 | COCH levels | GCST90468810 | 36.59 |
| 69 | Red blood cell count | GCST90018751 | 36.03 |
| 70 | PGLYRP1 levels | GCST90470219 | 35.51 |
| 71 | platelet count (minimum, inv-norm transformed) | GCST90476302 | 35.40 |
| 72 | ANGPT1/APP ratio | GCST90313260 | 35.37 |
| 73 | Platelet distribution width | GCST90002401 | 35.30 |
| 74 | Platelet count | GCST90018749 | 35.27 |
| 75 | CCN2/EDAR ratio | GCST90313711 | 35.08 |
| 76 | Basophil count | GCST90018726 | 34.66 |
| 77 | Plateletcrit | GCST004607 | 34.66 |
| 78 | ITGB1BP2/PTPN6 ratio | GCST90315218 | 33.96 |
| 79 | EDAR/PSRC1 ratio | GCST90314584 | 33.96 |
| 80 | Platelet distribution width | Blood count | UKBB00000648 | 33.95 |
| 81 | CD63/EDAR ratio | GCST90313864 | 33.61 |
| 82 | DNA methylation Hannum age acceleration | GCST90014289 | 33.32 |
| 83 | LCN2 levels | GCST90469747 | 33.31 |
| 84 | Red blood cell erythrocyte count (UKB data field 30010) | GCST90468098 | 33.30 |
| 85 | Subclinical hypothyroidism in pregnancy | GCST90435197 | 32.98 |
| 86 | CST3/DEFA1_DEFA1B ratio | GCST90314291 | 32.79 |
| 87 | Right-hemisphere somatomotor network to pallidum white-matter structural connectivity | GCST90302797 | 32.59 |
| 88 | CCN2/VEGFC ratio | GCST90313719 | 32.51 |
| 89 | CCL28 levels | GCST90468580 | 32.48 |
| 90 | EDAR/SPARC ratio | GCST90314588 | 31.89 |
| 91 | HSBP1 levels | GCST90469481 | 31.57 |
| 92 | HBEGF/SDC4 ratio | GCST90315037 | 31.19 |
| 93 | Platelet count | GCST004603 | 31.19 |
| 94 | Basophil percentage of granulocytes | GCST004634 | 30.90 |
| 95 | Heart failure, strict | FING00000606 | 30.82 |
| 96 | Dorsalgia | FING00000472 | 30.81 |
| 97 | red blood cell count (RBC, maximum, inv-norm transformed) | GCST90476345 | 30.80 |
| 98 | Mean corpuscular hemoglobin | GCST90002323 | 30.76 |
| 99 | Platelet count during third trimester of pregnancy | GCST90302226 | 30.68 |
| 100 | Telomere length (principal component 1) | GCST90435144 | 30.53 |
| 101 | Attention deficit hyperactivity disorder | GCST90568441 | 30.48 |
| 102 | CPXM1/MDK ratio | GCST90314221 | 30.42 |
| 103 | mean corpuscular hemoglobin concentration (MCHC, maximum, inv-norm transformed) | GCST90475454 | 30.30 |
| 104 | T1 FreeSurfer DK rh fusiform volume | GCST90385763 | 30.29 |
| 105 | ENO2/ITGB1BP2 ratio | GCST90314661 | 30.29 |
| 106 | DRAXIN levels | GCST90469038 | 30.16 |
| 107 | Red blood cell count | GCST90002364 | 30.15 |
| 108 | Operation code - bunion/hallus valgus surgery | Operations | UKBB00000551 | 29.90 |
| 109 | LCN2/PGLYRP1 ratio | GCST90315306 | 29.34 |
| 110 | Leisure screen time | GCST90104339 | 29.03 |
| 111 | mean corpuscular hemoglobin concentration (MCHC, mean, inv-norm transformed) | GCST90475458 | 28.80 |
| 112 | Nontoxic goitre/thyroid nodule | FING00000887 | 28.70 |
| 113 | CTF1/ITGB1BP2 ratio | GCST90314305 | 28.53 |
| 114 | PDGFA/SCARF1 ratio | GCST90315617 | 28.52 |
| 115 | Codeine or tramadol medication | FING00000311 | 28.39 |
| 116 | Spondylosis | FING00001327 | 28.38 |
| 117 | Platelet distribution width | GCST004616 | 28.28 |
| 118 | CRYGD levels | GCST90468876 | 28.25 |
| 119 | Frequency of drinking alcohol | Alcohol use | UKBB00000260 | 28.25 |
| 120 | mean corpuscular hemoglobin concentration (MCHC, minimum, inv-norm transformed) | GCST90475462 | 27.74 |
| 121 | Low back pain | FING00000730 | 27.60 |
| 122 | Depression medications | FING00000399 | 27.40 |
| 123 | GALNT5 levels | GCST90469298 | 27.35 |
| 124 | Nontoxic multinodular goitre | FING00000888 | 27.28 |
| 125 | Attention deficit hyperactivity disorder | GCST005362 | 27.21 |
| 126 | Blood cell traits latent factor 2 (red cell) | GCST90559244 | 26.80 |
| 127 | TREML2 levels | GCST90470962 | 26.78 |
| 128 | CXCL11 levels | GCST90468924 | 26.36 |
| 129 | FLT3/FLT3LG ratio | GCST90314859 | 26.21 |
| 130 | CXCL11/SDC4 ratio | GCST90314336 | 26.20 |
| 131 | CXCL6/DFFA ratio | GCST90314357 | 26.12 |
| 132 | Age at first sexual intercourse | GCST90000046 | 26.10 |
| 133 | ANGPT1/CPXM1 ratio | GCST90313262 | 26.10 |
| 134 | CAPS levels | GCST90468539 | 26.02 |
| 135 | BTC levels | GCST90468476 | 25.98 |
| 136 | Platelet count during postpartum period | GCST90302228 | 25.78 |
| 137 | PDGFA/SPARC ratio | GCST90315620 | 25.73 |
| 138 | IDP dMRI ProbtrackX ISOVF ifo l | GCST90004537 | 25.59 |
| 139 | CD84/TREML2 ratio | GCST90313919 | 25.50 |
| 140 | Gestational thrombocytopenia | GCST90302234 | 25.22 |
| 141 | Principal component-derived dietary pattern 45 | GCST90133050 | 25.18 |
| 142 | Number of operations, self-reported | Operations | UKBB00000539 | 25.11 |
| 143 | Mean platelet (thrombocyte) volume | Blood count | UKBB00000450 | 24.89 |
| 144 | red blood cell count (RBC, minimum, inv-norm transformed) | GCST90476353 | 24.73 |
| 145 | red blood cell count (RBC, mean, inv-norm transformed) | GCST90476349 | 24.73 |
| 146 | Osteoarthritis, localized (PheCode 740.1) | GCST90476254 | 24.65 |
| 147 | MPI/TACC3 ratio | GCST90315491 | 24.63 |
| 148 | CPXM1/DKK1 ratio | GCST90314218 | 24.60 |
| 149 | White blood cell count | GCST90018758 | 24.55 |
| 150 | Peak expiratory flow (PEF) | Spirometry | UKBB00000638 | 24.46 |
| 151 | white blood cell count (WBC, mean, inv-norm transformed) | GCST90476454 | 24.44 |
| 152 | SDC4/SELP ratio | GCST90315817 | 24.26 |
| 153 | PDGFA/SERPINE1 ratio | GCST90315618 | 24.22 |
| 154 | Lower back pain or/and sciatica | FING00000731 | 23.93 |
| 155 | METAP1D/VASH1 ratio | GCST90315429 | 23.79 |
| 156 | Mean platelet volume during second trimester of pregnancy | GCST90302230 | 23.73 |
| 157 | Number of days/week walked 10+ minutes | Physical activity | UKBB00000535 | 23.65 |
| 158 | APP/HBEGF ratio | GCST90313324 | 23.63 |
| 159 | HBEGF levels | GCST90469433 | 23.61 |
| 160 | Other intervertebral disk disorders | Other dorsopathies | UKBB00000612 | 23.55 |
| 161 | CEACAM8/RNASE3 ratio | GCST90314004 | 23.35 |
| 162 | Other and unspecified tonsillitis | FING00000954 | 23.29 |
| 163 | CCL28/PDGFB ratio | GCST90313695 | 23.18 |
| 164 | ANGPT1/CCN2 ratio | GCST90313261 | 23.17 |
| 165 | Red blood cell count | GCST004601 | 23.15 |
| 166 | Bursitis (PheCode 726.3) | GCST90476240 | 23.14 |
| 167 | aparc-a2009s lh area S-temporal-sup | GCST90003369 | 23.11 |
| 168 | Prescriptions - gliclazide | sulfonylurea,diabetes | UKBB00000684 | 23.06 |
| 169 | Mood [affective] disorders | FING00000836 | 23.03 |
| 170 | SPARC/TACC3 ratio | GCST90315872 | 22.99 |
| 171 | EDAR/F2R ratio | GCST90314577 | 22.88 |
| 172 | Mean platelet volume during first trimester of pregnancy | GCST90302229 | 22.85 |
| 173 | neutrophil (absolute count, maximum, inv-norm transformed) | GCST90475526 | 22.75 |
| 174 | Duration walking for pleasure | Physical activity | UKBB00000203 | 22.72 |
| 175 | PDGFB/SDC4 ratio | GCST90315626 | 22.69 |
| 176 | APP/CD40LG ratio | GCST90313319 | 22.63 |
| 177 | CDKN2D/ITGB1BP2 ratio | GCST90313987 | 22.61 |
| 178 | F2R/ITGB1BP2 ratio | GCST90314731 | 22.59 |
| 179 | CXCL11/CXCL13 ratio | GCST90314333 | 22.56 |
| 180 | Lupus erythematosus | FING00000739 | 22.47 |
| 181 | Red blood cell count | GCST90002403 | 22.36 |
| 182 | CRACR2A/IRAG2 ratio | GCST90314227 | 22.35 |
| 183 | TCN1 levels | GCST90470819 | 22.33 |
| 184 | White blood cell count | GCST90002375 | 22.20 |
| 185 | CCL2 levels | GCST90468581 | 22.11 |
| 186 | LCN2/RETN ratio | GCST90315308 | 22.08 |
| 187 | CD38 levels | GCST90468628 | 22.02 |
| 188 | TNFSF12 levels | GCST90470919 | 21.97 |
| 189 | LAT2/YES1 ratio | GCST90315282 | 21.95 |
| 190 | Number of sexual partners in opposite-sex sexual behavior | GCST90026480 | 21.64 |
| 191 | Chronic diseases of tonsils and adenoids | FING00000283 | 21.63 |
| 192 | CEACAM6 levels | GCST90468697 | 21.52 |
| 193 | Platelet count | GCST90002358 | 21.45 |
| 194 | FADD/MGLL ratio | GCST90314768 | 21.44 |
| 195 | CCL5/TACC3 ratio | GCST90313707 | 21.41 |
| 196 | Clonal haematopoiesis of indeterminate potential (DNMT3A mutation) | GCST90165271 | 21.41 |
| 197 | CDKN2D/TACC3 ratio | GCST90313992 | 21.26 |
| 198 | Nerve, nerve root and plexus disorders | FING00000862 | 21.17 |
| 199 | ITGB1BP2/MED18 ratio | GCST90315213 | 21.16 |
| 200 | IDP dMRI TBSS L1 Superior longitudinal fasciculus R | GCST90004115 | 21.08 |
| 201 | CXCL11/DKK1 ratio | GCST90314334 | 21.04 |
| 202 | Clonal haematopoiesis of indeterminate potential (with or without mosaic chromosomal alteration) | GCST90165267 | 21.02 |
| 203 | MAVS/ZBTB16 ratio | GCST90315401 | 20.69 |
| 204 | EDAR/PRDX5 ratio | GCST90314583 | 20.65 |
| 205 | CPXM1/LGMN ratio | GCST90314220 | 20.61 |
| 206 | PRG2 levels | GCST90470322 | 20.54 |
| 207 | neutrophil (absolute count, mean, inv-norm transformed) | GCST90475529 | 20.53 |
| 208 | Polyneuropathy in diabetes (PheCode 250.6) | GCST90475686 | 20.47 |
| 209 | Pain in joint | FING00001137 | 20.45 |
| 210 | Basophil count | GCST90002292 | 20.43 |
| 211 | Illnesses of siblings - Diabetes | Family history | UKBB00000350 | 20.29 |
| 212 | Arthropathies | FING00000107 | 20.26 |
| 213 | Whole body fat free mass (UKB data field 23101) | GCST90428120 | 20.24 |
| 214 | IPCEF1/SMAD1 ratio | GCST90315185 | 20.22 |
| 215 | DNM3 levels | GCST90469022 | 20.22 |
| 216 | Activities undertaken to treat depression | Depression | UKBB00000010 | 20.10 |
| 217 | BMI and adiposity (confirmatory factor analysis Factor 7) | GCST90309342 | 20.08 |
| 218 | Non-ischemic cardiomyopathy | FING00000873 | 20.05 |
| 219 | Birth weight | GCST007557 | 20.02 |
| 220 | Central pulse pressure | GCST90267387 | 19.95 |
| 221 | Frailty (Factor 2 - Unhealthy Lifestyle) | GCST90624048 | 19.94 |
| 222 | CD36 levels | GCST90468627 | 19.94 |
| 223 | Psoriasis vulgaris | GCST90018687 | 19.92 |
| 224 | EDAR/F11R ratio | GCST90314576 | 19.92 |
| 225 | Retention of urine | FING00001257 | 19.85 |
| 226 | Prescriptions - ACE inhibitor|anti-hypertensive | UKBB00000657 | 19.82 |
| 227 | COL2A1 levels | GCST90468816 | 19.78 |
| 228 | rfMRI connectivity (ICA100 edge 995) | GCST90005848 | 19.77 |
| 229 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 16) | GCST90320579 | 19.74 |
| 230 | Right-hemisphere somatomotor network to hippocampus white-matter structural connectivity | GCST90302798 | 19.73 |
| 231 | CD244/GP1BA ratio | GCST90313766 | 19.56 |
| 232 | VEGFA levels | GCST90471034 | 19.50 |
| 233 | Sleep apnoea | FING00001309 | 19.48 |
| 234 | CCL11/CCL2 ratio | GCST90313672 | 19.42 |
| 235 | CEP43/WASF1 ratio | GCST90314023 | 19.21 |
| 236 | Number of sexual partners in opposite-sex sexual behavior | GCST90026482 | 19.19 |
| 237 | ATP5IF1/DECR1 ratio | GCST90313382 | 19.17 |
| 238 | Other diseases of intestines | FING00001001 | 19.11 |
| 239 | DKK1/SERPINE1 ratio | GCST90314480 | 19.09 |
| 240 | CD300C/MANSC1 ratio | GCST90313791 | 19.09 |
| 241 | Red blood cell (erythrocyte) count | Blood count | UKBB00000747 | 19.00 |
| 242 | CRH levels | GCST90468862 | 18.98 |
| 243 | SDC4/SEMA4D ratio | GCST90315818 | 18.92 |
| 244 | rfMRI connectivity ICA-features 3 | GCST90006341 | 18.87 |
| 245 | IDP dMRI ProbtrackX L1 slf l | GCST90004267 | 18.79 |
| 246 | Other joint disorders | FING00001064 | 18.77 |
| 247 | Monocyte count | GCST90018747 | 18.76 |
| 248 | KIFBP/TACC3 ratio | GCST90315249 | 18.68 |
| 249 | GALNT10/TNFSF12 ratio | GCST90314916 | 18.60 |
| 250 | Pain in limb (PheCode 773) | GCST90476270 | 18.57 |
| 251 | mean platelet volume (MPV, maximum, inv-norm transformed) | GCST90475517 | 18.54 |
| 252 | CDKN1A/TACC3 ratio | GCST90313975 | 18.51 |
| 253 | ANGPT1/PDGFA ratio | GCST90313266 | 18.50 |
| 254 | Alcohol drinker status: current vs never (UKB data field 20117) | GCST90132924 | 18.48 |
| 255 | Prescriptions - sulfonylurea|diabetes | UKBB00000703 | 18.44 |
| 256 | AZU1/RNASE3 ratio | GCST90313428 | 18.35 |
| 257 | Bread type - White | Diet | UKBB00000106 | 18.35 |
| 258 | PRG3 levels | GCST90470323 | 18.31 |
| 259 | DKK1/VEGFA ratio | GCST90314483 | 18.26 |
| 260 | Plasma X-24947 levels in chronic kidney disease | GCST90266816 | 18.26 |
| 261 | Middle diffusion tensor imaging along the perivascular space index | GCST90455544 | 18.21 |
| 262 | Spread type: Butter and margarine spreads vs oil-based spreads (UKB data field 1428) | GCST90132951 | 18.19 |
| 263 | Hypothyroidism, drug reimbursement | FING00000655 | 18.15 |
| 264 | Tea with sugar liking | GCST90094857 | 18.15 |
| 265 | CD69/SNAP23 ratio | GCST90313886 | 18.12 |
| 266 | TNFRSF14 levels | GCST90470907 | 18.08 |
| 267 | CD300C/HAVCR2 ratio | GCST90313789 | 18.04 |
| 268 | ANXA3/EDAR ratio | GCST90313280 | 17.99 |
| 269 | RETN levels | GCST90470457 | 17.97 |
| 270 | Sleep apnea (MTAG) | GCST90267362 | 17.88 |
| 271 | PVALB levels | GCST90470393 | 17.88 |
| 272 | CNTNAP2/DPP6 ratio | GCST90314168 | 17.86 |
| 273 | SPARC/TJAP1 ratio | GCST90315873 | 17.76 |
| 274 | JAM3 levels | GCST90469660 | 17.75 |
| 275 | Pain (limb, back, neck, head abdominally) | FING00001135 | 17.71 |
| 276 | Cerebrospinal fluid sulfate* levels | GCST90318056 | 17.67 |
| 277 | ANGPT1/DKK1 ratio | GCST90313263 | 17.57 |
| 278 | Time spent watching television (TV) | Physical activity | UKBB00000821 | 17.56 |
| 279 | Number of non-cancer illnesses (standard GWA) | GCST90267290 | 17.55 |
| 280 | Nonspecific chest pain (PheCode 418) | GCST90475947 | 17.53 |
| 281 | Sleep apnoea, including avohilmo | FING00001310 | 17.43 |
| 282 | Principal component-derived dietary pattern 2 | GCST90133007 | 17.37 |
| 283 | CLEC11A levels | GCST90468764 | 17.36 |
| 284 | CST7 levels | GCST90468897 | 17.30 |
| 285 | PIK3AP1 levels | GCST90470233 | 17.20 |
| 286 | SIRPB1 levels | GCST90470640 | 17.16 |
| 287 | Soft tissue disorders | FING00001316 | 17.15 |
| 288 | Biological Mother: High blood pressure | GCST90475490 | 17.09 |
| 289 | MAP2 levels | GCST90469853 | 17.09 |
| 290 | DEFA1 or DEFA1B levels | GCST90468979 | 17.07 |
| 291 | CCN2/DKK1 ratio | GCST90313710 | 17.06 |
| 292 | DAG1/F2R ratio | GCST90314374 | 16.98 |
| 293 | Viral hepatitis C (PheCode 70.3) | GCST90475553 | 16.98 |
| 294 | Mean platelet volume during third trimester of pregnancy | GCST90302231 | 16.96 |
| 295 | AARSD1/PIK3AP1 ratio | GCST90313129 | 16.94 |
| 296 | Basophil percentage of white cells | GCST90002380 | 16.92 |
| 297 | CA4/TNFSF12 ratio | GCST90313589 | 16.90 |
| 298 | Left-hemisphere somatomotor network to amygdala white-matter structural connectivity | GCST90302687 | 16.88 |
| 299 | SNAP23/ZBTB16 ratio | GCST90315858 | 16.88 |
| 300 | Ankle spacing width (left) | Bone-densitometry of heel | UKBB00000033 | 16.76 |
| 301 | F-caffeinated/sweet liking (derived food-liking factor) | GCST90094720 | 16.75 |
| 302 | Sleep apnea syndrome | GCST90267361 | 16.69 |
| 303 | CXCL11/VTA1 ratio | GCST90314337 | 16.68 |
| 304 | Vascular/heart problems diagnosed by doctor - High blood pressure | Medical conditions | UKBB00000898 | 16.67 |
| 305 | CASP3/SERPINE1 ratio | GCST90313643 | 16.66 |
| 306 | Right-hemisphere salience/ventral attention network to right-hemisphere default mode network white-matter structural connectivity | GCST90302816 | 16.66 |
| 307 | CRELD2/F2R ratio | GCST90314254 | 16.63 |
| 308 | IL2RA levels | GCST90469585 | 16.62 |
| 309 | Mean platelet volume | GCST90002395 | 16.59 |
| 310 | Mean reticulocyte volume | GCST90025975 | 16.58 |
| 311 | Blood cell traits latent factor 10 (platelet) | GCST90559252 | 16.49 |
| 312 | EBAG9/FKBP5 ratio | GCST90314564 | 16.47 |
| 313 | EDAR/TXNDC5 ratio | GCST90314593 | 16.46 |
| 314 | rfMRI connectivity ICA-features 6 | GCST90006344 | 16.32 |
| 315 | Cerebrospinal fluid 3-hydroxyhexanoate levels | GCST90318108 | 16.31 |
| 316 | DAG1/PDGFA ratio | GCST90314378 | 16.28 |
| 317 | CNTNAP2/DPP10 ratio | GCST90314167 | 16.19 |
| 318 | CALCOCO1/MAP3K5 ratio | GCST90313605 | 16.19 |
| 319 | Avocado liking | GCST90094694 | 16.16 |
| 320 | Average weekly beer plus cider intake | Alcohol | UKBB00000082 | 16.07 |
| 321 | ANGPT1/EGF ratio | GCST90313264 | 16.06 |
| 322 | Non-cancer illness code, self-reported - hypertension | Medical conditions | UKBB00000517 | 16.05 |
| 323 | Soy sauce liking | GCST90094844 | 16.04 |
| 324 | Tonsillectomy and adenotomy | FING00001367 | 16.02 |
| 325 | Mean platelet thrombocyte volume (UKB data field 30100) | GCST90468087 | 15.99 |
| 326 | CLIP2/NT5C3A ratio | GCST90314129 | 15.93 |
| 327 | Monocyte count | GCST90002341 | 15.90 |
| 328 | BCAM/ICAM4 ratio | GCST90313472 | 15.90 |
| 329 | FCER2/TREML2 ratio | GCST90314792 | 15.88 |
| 330 | Pain (PheCode 338) | GCST90475836 | 15.87 |
| 331 | Alcohol drinker status: current or former vs never (UKB data field 20117) | GCST90132923 | 15.87 |
| 332 | C3 levels | GCST90281041 | 15.83 |
| 333 | CLC levels | GCST90468762 | 15.82 |
| 334 | EGLN1/PIK3AP1 ratio | GCST90314619 | 15.82 |
| 335 | CDKN2D/MANF ratio | GCST90313989 | 15.75 |
| 336 | Types of transport used (excluding work) - Public transport | Physical activity | UKBB00000878 | 15.72 |
| 337 | Depression or dysthymia | FING00000400 | 15.71 |
| 338 | Other symptoms of respiratory system (PheCode 512) | GCST90476039 | 15.70 |
| 339 | Other dorsopathies, not elsewhere classified | FING00001041 | 15.70 |
| 340 | Viral hepatitis (PheCode 70) | GCST90475552 | 15.70 |
| 341 | Pain in joint (PheCode 745) | GCST90476262 | 15.69 |
| 342 | Attention deficit hyperactivity disorder (adjusted for age, sex) | GCST90275147 | 15.68 |
| 343 | Brain glioblastoma, excluding all cancers (controls excluding all cancers) | FING00000225 | 15.68 |
| 344 | Ankle spacing width (right) | Bone-densitometry of heel | UKBB00000034 | 15.66 |
| 345 | white blood cell count (WBC, minimum, inv-norm transformed) | GCST90476457 | 15.60 |
| 346 | Volume of right cortical nucleus | GCST90475030 | 15.60 |
| 347 | CXCL6 levels | GCST90468933 | 15.57 |
| 348 | Leg fat mass (right) | Impedance measures | UKBB00000390 | 15.53 |
| 349 | Other diseases of upper respiratory tract | FING00001012 | 15.48 |
| 350 | CCN2/HBEGF ratio | GCST90313713 | 15.43 |
| 351 | Weight (UKB data field 21002) | GCST90468183 | 15.42 |
| 352 | ENO2/TXNDC5 ratio | GCST90314671 | 15.39 |
| 353 | CPXM1/HBEGF ratio | GCST90314219 | 15.37 |
| 354 | Biological Mother: Cancer, Skin | GCST90475487 | 15.36 |
| 355 | Basophil count | GCST90025997 | 15.31 |
| 356 | PSRC1 levels | GCST90470365 | 15.29 |
| 357 | FOXO1/MAP4K5 ratio | GCST90314872 | 15.27 |
| 358 | Age at first sexual intercourse | GCST90000047 | 15.24 |
| 359 | Birth weight known - No | Early life factors | UKBB00000096 | 15.22 |
| 360 | VSTM1 levels | GCST90471055 | 15.20 |
| 361 | Immature fraction of reticulocytes | GCST004628 | 15.20 |
| 362 | Mean platelet volume | GCST004599 | 15.18 |
| 363 | AXIN1/DOK2 ratio | GCST90313406 | 15.17 |
| 364 | F2R/TNFRSF14 ratio | GCST90314739 | 15.13 |
| 365 | GRAP2/SRC ratio | GCST90314989 | 15.12 |
| 366 | SERPINE1/SMAD1 ratio | GCST90315833 | 15.11 |
| 367 | CLEC4C levels | GCST90468772 | 15.05 |
| 368 | Annual healthcare cost | GCST90292604 | 15.05 |
| 369 | MGLL/PLA2G4A ratio | GCST90315439 | 15.00 |
| 370 | ITGB1BP2 levels | GCST90469642 | 14.99 |
| 371 | Champagne or white wine consumption (glasses per month) (UKB data field 1578, 4418) | GCST90132986 | 14.96 |
| 372 | IDP dMRI TBSS L2 Fornix | GCST90004128 | 14.95 |
| 373 | CFC1 levels | GCST90468724 | 14.95 |
| 374 | ATP5IF1/METAP1D ratio | GCST90313391 | 14.95 |
| 375 | Thyrotoxicosis with toxic multinodular goitre | FING00001362 | 14.89 |
| 376 | CLEC1B/DKK1 ratio | GCST90314088 | 14.89 |
| 377 | CXCL3/CXCL5 ratio | GCST90314344 | 14.87 |
| 378 | Tea difference liking | GCST90094855 | 14.87 |
| 379 | Alcohol consumption | GCST90133003 | 14.85 |
| 380 | CCN2/SPINT2 ratio | GCST90313716 | 14.83 |
| 381 | JAM2/TNFRSF14 ratio | GCST90315240 | 14.82 |
| 382 | NUDT5/TXNRD1 ratio | GCST90315582 | 14.81 |
| 383 | Spondylopathies (FG) | FING00001326 | 14.79 |
| 384 | TNFRSF13C/TNFSF13B ratio | GCST90315934 | 14.78 |
| 385 | FABP5/PPCDC ratio | GCST90314763 | 14.75 |
| 386 | DEFA1_DEFA1B/PTGDS ratio | GCST90314455 | 14.75 |
| 387 | AXIN1/MAP2K6 ratio | GCST90313413 | 14.71 |
| 388 | IDP dMRI TBSS OD Fornix | GCST90004407 | 14.70 |
| 389 | Oral glucose tolerance test-2h | GCST90297790 | 14.68 |
| 390 | DAG1/DKK1 ratio | GCST90314373 | 14.65 |
| 391 | PPP1R2/TMSB10 ratio | GCST90315721 | 14.61 |
| 392 | CD69/CHMP1A ratio | GCST90313868 | 14.60 |
| 393 | CD22/SEMA7A ratio | GCST90313759 | 14.54 |
| 394 | Hypertension | circulatory system | UKBB00000334 | 14.51 |
| 395 | Waist circumference (UKB data field 48) | GCST90468182 | 14.51 |
| 396 | SELL levels | GCST90470567 | 14.51 |
| 397 | SIGLEC8 levels | GCST90470636 | 14.46 |
| 398 | PDGFA levels | GCST90470188 | 14.45 |
| 399 | PDGFA/SNAP23 ratio | GCST90315619 | 14.44 |
| 400 | Essential hypertension | circulatory system | UKBB00000209 | 14.44 |
| 401 | Breast cancer | GCST007236 | 14.43 |
| 402 | White blood cell count | GCST004610 | 14.41 |
| 403 | DKK1 levels | GCST90468997 | 14.41 |
| 404 | Attention deficit hyperactivity disorder (ADuLT model adjusted for sex) | GCST90275136 | 14.40 |
| 405 | Cough on most days | Medical information | UKBB00000153 | 14.39 |
| 406 | CCN2/TPP1 ratio | GCST90313718 | 14.39 |
| 407 | F-sweetened coffee drink liking (derived food-liking factor) | GCST90094853 | 14.38 |
| 408 | Red blood cell count | GCST90278641 | 14.36 |
| 409 | Heart failure and bmi 25plus | FING00000603 | 14.35 |
| 410 | CD22/FOLR2 ratio | GCST90313758 | 14.32 |
| 411 | CRADD/FADD ratio | GCST90314237 | 14.30 |
| 412 | Blood cell traits latent factor 18 (platelet) | GCST90559260 | 14.30 |
| 413 | monocyte (absolute count, maximum, inv-norm transformed) | GCST90475499 | 14.28 |
| 414 | GOLGA3 levels | GCST90469375 | 14.28 |
| 415 | Treatment/medication code - ramipril | Medications | UKBB00000856 | 14.27 |
| 416 | IDP T1 FAST ROIs L cerebellum V | GCST90002564 | 14.26 |
| 417 | Right-hemisphere dorsal attention network to right-hemisphere default mode network white-matter structural connectivity | GCST90302805 | 14.26 |
| 418 | Length of mobile phone use | Electronic device use | UKBB00000403 | 14.26 |
| 419 | FCRL1/TREML2 ratio | GCST90314797 | 14.23 |
| 420 | ITGB5/VSIR ratio | GCST90315235 | 14.17 |
| 421 | Age when finished full-time education (standard GWA) | GCST90267280 | 14.14 |
| 422 | Number of treatments/medications taken | Medications | UKBB00000542 | 14.12 |
| 423 | ITGB1BP2 levels | GCST90012058 | 14.11 |
| 424 | EDAR/ENO2 ratio | GCST90314574 | 14.08 |
| 425 | Arm fat percentage (left) | Impedance measures | UKBB00000045 | 14.06 |
| 426 | Pain type(s) experienced in last month - None of the above | Pain | UKBB00000631 | 14.06 |
| 427 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 119) | GCST90320938 | 14.05 |
| 428 | Depression | FING00000398 | 14.04 |
| 429 | IDP dMRI ProbtrackX ICVF str r | GCST90004399 | 14.04 |
| 430 | SCRN1 levels | GCST90470556 | 13.97 |
| 431 | Right-hemisphere control network to amygdala white-matter structural connectivity | GCST90302841 | 13.96 |
| 432 | Breathing problems during period of job | Employment history | UKBB00000111 | 13.94 |
| 433 | EBAG9/EDAR ratio | GCST90314563 | 13.93 |
| 434 | CLEC1B/NSFL1C ratio | GCST90314099 | 13.89 |
| 435 | Basophill percentage | Blood count | UKBB00000087 | 13.86 |
| 436 | Been in a confiding relationship as an adult | Traumatic events | UKBB00000088 | 13.86 |
| 437 | Snoring | Sleep | UKBB00000784 | 13.84 |
| 438 | SPINT2 levels | GCST90470728 | 13.84 |
| 439 | Osteoarthrosis (PheCode 740) | GCST90476253 | 13.84 |
| 440 | SEMA4D levels | GCST90470573 | 13.79 |
| 441 | Neutrophil count | GCST90002352 | 13.76 |
| 442 | DNAJC6 levels | GCST90469017 | 13.69 |
| 443 | Principal component-derived dietary pattern 8 | GCST90133013 | 13.68 |
| 444 | REST UKBBICA NODEamps25 0005 | GCST90385488 | 13.68 |
| 445 | CD244/TREML2 ratio | GCST90313767 | 13.65 |
| 446 | PEAR1/TREML2 ratio | GCST90315645 | 13.65 |
| 447 | CPXM1 levels | GCST90468849 | 13.58 |
| 448 | SERPINE2 levels | GCST90470597 | 13.58 |
| 449 | CD69/CDKN2D ratio | GCST90313866 | 13.56 |
| 450 | Biological Grandparent (paternal): Diabetes / Sugar | GCST90475549 | 13.56 |
| 451 | TRIAP1 levels | GCST90470963 | 13.56 |
| 452 | SFTPA2 levels | GCST90470613 | 13.55 |
| 453 | White blood cell (leukocyte) count | Blood count | UKBB00000913 | 13.52 |
| 454 | CXCL5/SPARC ratio | GCST90314355 | 13.51 |
| 455 | SERPINE1/SPARC ratio | GCST90315834 | 13.50 |
| 456 | Basal metabolic rate (UKB data field 23105) | GCST90468159 | 13.49 |
| 457 | CLEC1B/VTA1 ratio | GCST90314107 | 13.48 |
| 458 | Humerus length to body height ratio | GCST90270259 | 13.47 |
| 459 | IDP dMRI TBSS FA Fornix | GCST90003882 | 13.44 |
| 460 | CD58/SIRPB1 ratio | GCST90313855 | 13.42 |
| 461 | TFF1/TFF2 ratio | GCST90315914 | 13.33 |
| 462 | Any mental disorder | FING00000100 | 13.30 |
| 463 | EDAR/TMSB10 ratio | GCST90314590 | 13.28 |
| 464 | ACY1/SCLY ratio | GCST90313165 | 13.27 |
| 465 | DIPK2B levels | GCST90468996 | 13.27 |
| 466 | Irregular menses | FING00000701 | 13.26 |
| 467 | HTRA2/TRIAP1 ratio | GCST90315099 | 13.25 |
| 468 | Patient classification on admission (recoded) - Inpatient | Summary Administration | UKBB00000637 | 13.25 |
| 469 | Paradoxical eczema in biologic-treated plaque psoriasis | GCST90162550 | 13.25 |
| 470 | TACC3/TRIAP1 ratio | GCST90315901 | 13.22 |
| 471 | EGFL7 levels | GCST90469083 | 13.19 |
| 472 | Artrosis, including avohilmo | FING00000112 | 13.19 |
| 473 | LYN/TACC3 ratio | GCST90315350 | 13.18 |
| 474 | GP6/TMSB10 ratio | GCST90314975 | 13.17 |
| 475 | CLEC1B/HEXIM1 ratio | GCST90314093 | 13.17 |
| 476 | Snoring | GCST009760 | 13.14 |
| 477 | CSF3R levels | GCST90468885 | 13.13 |
| 478 | PAPPA levels | GCST90470157 | 13.13 |
| 479 | Overall health rating | General health | UKBB00000621 | 13.13 |
| 480 | Right-hemisphere somatomotor network to thalamus white-matter structural connectivity | GCST90302794 | 13.12 |
| 481 | Other disorders of the musculoskeletal system and connective tissue | FING00001038 | 13.10 |
| 482 | ATP5IF1/HSPA1A ratio | GCST90313388 | 13.10 |
| 483 | Basophil count | GCST90002379 | 13.10 |
| 484 | Sleep apnea (MTAG) (adjusted for BMI) | GCST90267364 | 13.09 |
| 485 | Illnesses of siblings - None of the above (group 1) | Family history | UKBB00000353 | 13.09 |
| 486 | TGFB1 levels | GCST90470843 | 13.09 |
| 487 | CD40LG/EDAR ratio | GCST90313818 | 13.08 |
| 488 | ANXA4/FADD ratio | GCST90313291 | 13.05 |
| 489 | Age first had sexual intercourse | Sexual factors | UKBB00000014 | 13.04 |
| 490 | Right-hemisphere dorsal attention network to amygdala white-matter structural connectivity | GCST90302811 | 13.04 |
| 491 | NTF4 levels | GCST90470095 | 12.99 |
| 492 | Other localized connective tissue disorders | FING00001066 | 12.98 |
| 493 | Weight | Body size measures | UKBB00000909 | 12.98 |
| 494 | Other and/or unspecified nontoxic goitre | FING00000958 | 12.96 |
| 495 | Leg fat mass (left) | Impedance measures | UKBB00000389 | 12.94 |
| 496 | X-13435 levels | GCST90243811 | 12.94 |
| 497 | CLEC1B/RWDD1 ratio | GCST90314102 | 12.93 |
| 498 | Treatment or medication use - metformin (UKB data field 20003_1140884600) | GCST90042245 | 12.92 |
| 499 | Weight | Impedance measures | UKBB00000910 | 12.91 |
| 500 | Arm fat percentage (right) | Impedance measures | UKBB00000046 | 12.90 |
| 501 | Other embolism and thrombosis | FING00001043 | 12.89 |
| 502 | SNAP29/TJAP1 ratio | GCST90315861 | 12.88 |
| 503 | Sleep disorders (PheCode 327) | GCST90475823 | 12.87 |
| 504 | SCPEP1 levels | GCST90470553 | 12.86 |
| 505 | CCDC50 levels | GCST90468561 | 12.86 |
| 506 | Neutrophil count | GCST90018748 | 12.86 |
| 507 | Anxiety disorders (more control exclusions) | FING00000098 | 12.86 |
| 508 | Venous thromboembolism | FING00001427 | 12.82 |
| 509 | Alcohol intake versus 10 years previously | Alcohol | UKBB00000024 | 12.82 |
| 510 | CCN2/ENO2 ratio | GCST90313712 | 12.81 |
| 511 | FHIT/MAX ratio | GCST90314818 | 12.80 |
| 512 | CETN2/PRTFDC1 ratio | GCST90314030 | 12.80 |
| 513 | Gonarthrosis, primary, with knee surgery | FING00000586 | 12.79 |
| 514 | CXCL5/SERPINE1 ratio | GCST90314354 | 12.74 |
| 515 | GFER/VASH1 ratio | GCST90314922 | 12.72 |
| 516 | CXCL5/EDAR ratio | GCST90314349 | 12.68 |
| 517 | FOXO1/NFATC1 ratio | GCST90314873 | 12.67 |
| 518 | CD40LG levels | GCST90468632 | 12.67 |
| 519 | DAG1/SCARF1 ratio | GCST90314381 | 12.66 |
| 520 | Salty food liking | GCST90094828 | 12.64 |
| 521 | Dorsopathies | FING00000473 | 12.63 |
| 522 | IL15/NCR1 ratio | GCST90315150 | 12.60 |
| 523 | monocyte (absolute count, mean, inv-norm transformed) | GCST90475502 | 12.59 |
| 524 | GP5 levels | GCST90469383 | 12.59 |
| 525 | EDAR/IPCEF1 ratio | GCST90314578 | 12.58 |
| 526 | CXCL12/TIMP3 ratio | GCST90314338 | 12.57 |
| 527 | CASP3/PDGFA ratio | GCST90313637 | 12.56 |
| 528 | Liver iron content | GCST90016674 | 12.56 |
| 529 | ENO2/RWDD1 ratio | GCST90314667 | 12.51 |
| 530 | Prescriptions - calcium channel blocker|dihydropyridine|anti-hypertensive | UKBB00000673 | 12.50 |
| 531 | DAB2/FKBP5 ratio | GCST90314363 | 12.50 |
| 532 | Bread type: White (UKB data field 1448_1) | GCST90132964 | 12.49 |
| 533 | Soya milk liking | GCST90094845 | 12.48 |
| 534 | SLAMF8 levels | GCST90470652 | 12.46 |
| 535 | ANXA3/HCLS1 ratio | GCST90313282 | 12.45 |
| 536 | EDAR/EGF ratio | GCST90314573 | 12.45 |
| 537 | MECR levels | GCST90469879 | 12.44 |
| 538 | Spondylopathies | FING00001325 | 12.41 |
| 539 | FHIT/PMVK ratio | GCST90314822 | 12.39 |
| 540 | Platelet count at delivery | GCST90302227 | 12.37 |
| 541 | LCN2/S100A12 ratio | GCST90315309 | 12.35 |
| 542 | Lymphocyte percentage of white cells | GCST90002389 | 12.35 |
| 543 | SERPINB6 levels | GCST90470591 | 12.34 |
| 544 | Number of incorrect matches in round | Pairs matching | UKBB00000538 | 12.31 |
| 545 | IDP dMRI TBSS L3 Fornix | GCST90004176 | 12.30 |
| 546 | FGF2/HBEGF ratio | GCST90314811 | 12.28 |
| 547 | CRADD/EDAR ratio | GCST90314235 | 12.27 |
| 548 | X-12749 levels | GCST90243770 | 12.27 |
| 549 | CRYBB1 levels | GCST90468874 | 12.26 |
| 550 | neutrophil (absolute count, minimum, inv-norm transformed) | GCST90475532 | 12.26 |
| 551 | Salt added to food | Diet | UKBB00000762 | 12.25 |
| 552 | Other soft tissue disorders, not elsewhere classified | FING00001099 | 12.25 |
| 553 | Sedentary behavior at work | GCST90104345 | 12.23 |
| 554 | CD84/SDC4 ratio | GCST90313916 | 12.23 |
| 555 | Alcohol drinker status - Never | Alcohol | UKBB00000022 | 12.15 |
| 556 | Bread type: White vs wholemeal/wholegrain and brown (UKB data field 1448) | GCST90132967 | 12.11 |
| 557 | DTI TBSS L2 Anterior limb of internal capsule L | GCST90384493 | 12.09 |
| 558 | BCR/NFATC1 ratio | GCST90313496 | 12.09 |
| 559 | Major depressive disorder (probable) | GCST005904 | 12.06 |
| 560 | CLEC1B/SNAP29 ratio | GCST90314103 | 12.05 |
| 561 | IDP dMRI TBSS MD Fornix | GCST90004032 | 12.03 |
| 562 | SCARF1 levels | GCST90470536 | 12.03 |
| 563 | Illnesses of father - Diabetes | Family history | UKBB00000341 | 12.00 |
| 564 | ADAM8 levels | GCST90468220 | 11.97 |
| 565 | Use of hypnotics and sedatives | FING00001411 | 11.96 |
| 566 | ANGPT1/SERPINE1 ratio | GCST90313269 | 11.96 |
| 567 | Lymphocyte percentage (UKB data field 30180) | GCST90468083 | 11.96 |
| 568 | CD69/EDAR ratio | GCST90313875 | 11.90 |
| 569 | MAX/STK24 ratio | GCST90315404 | 11.89 |
| 570 | Chronic airway obstruction (PheCode 496) | GCST90476027 | 11.89 |
| 571 | APP/CCL28 ratio | GCST90313317 | 11.88 |
| 572 | Brussel sprout liking | GCST90094714 | 11.87 |
| 573 | NRCAM/PCDH17 ratio | GCST90315553 | 11.84 |
| 574 | Vigorous physical activity | GCST006098 | 11.83 |
| 575 | Nap during day | Sleep | UKBB00000492 | 11.82 |
| 576 | Snoring | GCST009763 | 11.82 |
| 577 | Illness, injury, bereavement, stress in last 2 years - None of the above | Mental health | UKBB00000339 | 11.81 |
| 578 | CD22 levels | GCST90468610 | 11.79 |
| 579 | Trunk fat mass | Impedance measures | UKBB00000863 | 11.79 |
| 580 | ROBO1 levels | GCST90470489 | 11.78 |
| 581 | SELP levels | GCST90470569 | 11.78 |
| 582 | WFDC1 levels | GCST90471074 | 11.78 |
| 583 | Arm fat mass (right) | Impedance measures | UKBB00000044 | 11.78 |
| 584 | Medication use (vasodilators used in cardiac diseases) | GCST90018763 | 11.76 |
| 585 | DNA methylation PhenoAge acceleration | GCST90014292 | 11.76 |
| 586 | Poultry consumption | GCST90132996 | 11.75 |
| 587 | FLT1/VEGFA ratio | GCST90314858 | 11.74 |
| 588 | Whole body fat mass | Impedance measures | UKBB00000914 | 11.72 |
| 589 | MITD1/RHOC ratio | GCST90315453 | 11.70 |
| 590 | HIP1R levels | GCST90469453 | 11.66 |
| 591 | CLEC1B/LGALS8 ratio | GCST90314096 | 11.66 |
| 592 | FKBP4/RWDD1 ratio | GCST90314840 | 11.65 |
| 593 | Treatment/medication code - gliclazide | Medications | UKBB00000846 | 11.65 |
| 594 | Gastro-oesophageal reflux disease | FING00000564 | 11.64 |
| 595 | TP53BP1 levels | GCST90470936 | 11.63 |
| 596 | MAP4K5 levels | GCST90469855 | 11.62 |
| 597 | Monocyte count | Blood count | UKBB00000479 | 11.62 |
| 598 | Parental longevity (father's age at death) | GCST006700 | 11.62 |
| 599 | Leg predicted mass (left) | Impedance measures | UKBB00000396 | 11.60 |
| 600 | Birth weight known - Yes - pounds and ounces | Early life factors | UKBB00000097 | 11.59 |
| 601 | Educational attainment (confirmatory factor analysis Factor 10) | GCST90309344 | 11.57 |
| 602 | CXCL10/CXCL11 ratio | GCST90314330 | 11.57 |
| 603 | Prescriptions - biguanides|diabetes | UKBB00000671 | 11.55 |
| 604 | Episodal and paroxysmal disorders | FING00000514 | 11.54 |
| 605 | Occupational attainment | GCST90102253 | 11.53 |
| 606 | Prescriptions - metformin | biguanides,diabetes | UKBB00000692 | 11.53 |
| 607 | Frequency of friend/family visits | Social support | UKBB00000262 | 11.52 |
| 608 | IL15 levels | GCST90469556 | 11.51 |
| 609 | Hypermetropia (PheCode 367.8) | GCST90475882 | 11.50 |
| 610 | BCR/VASH1 ratio | GCST90313499 | 11.50 |
| 611 | VEGFC levels | GCST90471036 | 11.50 |
| 612 | FCRL1 levels | GCST90469205 | 11.49 |
| 613 | Frequency of stair climbing in last 4 weeks | Physical activity | UKBB00000266 | 11.47 |
| 614 | ENG/NCAM2 ratio | GCST90314647 | 11.46 |
| 615 | TPD52L2 levels | GCST90470942 | 11.45 |
| 616 | BCAM/PCDH17 ratio | GCST90313475 | 11.44 |
| 617 | Mean corpuscular hemoglobin concentration | GCST90002328 | 11.43 |
| 618 | Neutrophill count | Blood count | UKBB00000497 | 11.41 |
| 619 | Left-hemisphere somatomotor network to left-hemisphere default mode network white-matter structural connectivity | GCST90302674 | 11.41 |
| 620 | BA-exvivo rh volume MT | GCST90002860 | 11.39 |
| 621 | Paracetamol of NSAID medication | FING00001145 | 11.39 |
| 622 | Taking other prescription medications | Medication | UKBB00000813 | 11.33 |
| 623 | RETN levels | GCST90012034 | 11.32 |
| 624 | Thyroid peroxidase antibody positivity with euthyroid in pregnancy | GCST90435203 | 11.31 |
| 625 | CXCL5/PPIB ratio | GCST90314352 | 11.31 |
| 626 | Myeloid white cell count | GCST004626 | 11.31 |
| 627 | ERBIN/LYN ratio | GCST90314694 | 11.30 |
| 628 | Septal defects | FING00001293 | 11.30 |
| 629 | Lymphocyte percentage | Blood count | UKBB00000412 | 11.28 |
| 630 | MGLL levels | GCST90469901 | 11.27 |
| 631 | Other disorders of veins | FING00001040 | 11.26 |
| 632 | Pain type(s) experienced in last month - Headache | Pain | UKBB00000627 | 11.26 |
| 633 | Arm fat mass (left) | Impedance measures | UKBB00000043 | 11.26 |
| 634 | CLIP2/DAB2 ratio | GCST90314124 | 11.26 |
| 635 | Waist circumference | Body size measures | UKBB00000904 | 11.25 |
| 636 | Leg fat-free mass (left) | Impedance measures | UKBB00000393 | 11.24 |
| 637 | ABHD14B/SCRN1 ratio | GCST90313145 | 11.21 |
| 638 | Cereal bar liking | GCST90094728 | 11.20 |
| 639 | LZTFL1 levels | GCST90469834 | 11.20 |
| 640 | F-healthy breakfast food liking (derived food-liking factor) | GCST90094780 | 11.20 |
| 641 | Immature fraction of reticulocytes | GCST90002387 | 11.20 |
| 642 | Hypertension | GCST90468135 | 11.19 |
| 643 | Red wine consumption (glasses per month) (UKB data field 1578, 4419) | GCST90132987 | 11.19 |
| 644 | Major dietary changes in the last 5 years - No | Diet | UKBB00000421 | 11.18 |
| 645 | PPP1R2/TACC3 ratio | GCST90315719 | 11.17 |
| 646 | ITGB1BP2/TIA1 ratio | GCST90315222 | 11.16 |
| 647 | CD79B/ICAM3 ratio | GCST90313901 | 11.13 |
| 648 | GP1BA/HBEGF ratio | GCST90314956 | 11.11 |
| 649 | BMI (standard GWA) | GCST90267268 | 11.11 |
| 650 | Qualifications - None of the above | Education | UKBB00000729 | 11.11 |
| 651 | Number of sexual partners in opposite-sex sexual behavior | GCST90026481 | 11.09 |
| 652 | Pulmonary heart disease (PheCode 415) | GCST90475942 | 11.07 |
| 653 | KIF22 levels | GCST90469682 | 11.05 |
| 654 | DAG1/HBEGF ratio | GCST90314376 | 11.03 |
| 655 | LYN/YES1 ratio | GCST90315351 | 11.01 |
| 656 | Frailty index | GCST90020053 | 11.00 |
| 657 | Right-hemisphere visual network to pallidum white-matter structural connectivity | GCST90302784 | 10.99 |
| 658 | Immature reticulocyte fraction (UKB data field 30280) | GCST90468079 | 10.98 |
| 659 | BAX/MAX ratio | GCST90313466 | 10.98 |
| 660 | Immature reticulocyte fraction | Blood count | UKBB00000355 | 10.94 |
| 661 | Types of transport used (excluding work) - Walk | Physical activity | UKBB00000879 | 10.94 |
| 662 | EDAR/SERPINB1 ratio | GCST90314586 | 10.92 |
| 663 | ENO2/SCRN1 ratio | GCST90314668 | 10.91 |
| 664 | DAG1 levels | GCST90468943 | 10.90 |
| 665 | SH2B3/TBL1X ratio | GCST90315841 | 10.90 |
| 666 | T1 FreeSurfer a2009s rh S temporal sup volume | GCST90385110 | 10.89 |
| 667 | MZB1 levels | GCST90469987 | 10.88 |
| 668 | Other cataract | Disorders of lens | UKBB00000602 | 10.85 |
| 669 | CXCL11/ITGB1BP2 ratio | GCST90314335 | 10.85 |
| 670 | EBAG9/MITD1 ratio | GCST90314566 | 10.83 |
| 671 | DSG3/FABP9 ratio | GCST90314559 | 10.82 |
| 672 | Erectile dysfunction [ED] (PheCode 605) | GCST90476161 | 10.81 |
| 673 | X-12510--2-aminooctanoic acid levels | GCST90243748 | 10.79 |
| 674 | Spleen volume | GCST90016667 | 10.79 |
| 675 | ITGB1BP2/MITD1 ratio | GCST90315214 | 10.78 |
| 676 | MEP1A levels | GCST90469887 | 10.78 |
| 677 | CANT1/NUDT5 ratio | GCST90313619 | 10.78 |
| 678 | Osteitis deformans and osteopathies associated with other disorders classified elsewhere (PheCode 731) | GCST90476246 | 10.78 |
| 679 | CD40LG/SERPINE1 ratio | GCST90313826 | 10.77 |
| 680 | FHIT levels | GCST90469238 | 10.76 |
| 681 | ESAM levels | GCST90469152 | 10.76 |
| 682 | PPP1R12A/SPARC ratio | GCST90315712 | 10.75 |
| 683 | Trunk fat mass (UKB data field 23128) | GCST90468180 | 10.75 |
| 684 | Insomnia complaints | GCST004695 | 10.75 |
| 685 | IDP dMRI TBSS ICVF Superior fronto-occipital fasciculus R | GCST90004369 | 10.73 |
| 686 | ANGPT1 levels | GCST90468300 | 10.72 |
| 687 | BDNF levels | GCST90468437 | 10.71 |
| 688 | IDP dMRI ProbtrackX ISOVF ifo r | GCST90004538 | 10.69 |
| 689 | Pyruvate levels (UKB data field 23472) | GCST90269569 | 10.67 |
| 690 | Monocyte count | GCST004625 | 10.67 |
| 691 | Diabetes mellitus (UKB data field 2443) | GCST90043627 | 10.65 |
| 692 | REST UKBBICA NODEamps25 0009 | GCST90385492 | 10.64 |
| 693 | Right-hemisphere visual network to right-hemisphere default mode network white-matter structural connectivity | GCST90302780 | 10.64 |
| 694 | HBEGF/PDGFA ratio | GCST90315033 | 10.61 |
| 695 | Gastroesophageal reflux disease | GCST90000514 | 10.58 |
| 696 | Treatment/medication code - metformin | Medications | UKBB00000851 | 10.57 |
| 697 | EDAR/SNAP23 ratio | GCST90314587 | 10.56 |
| 698 | CEP20 levels | GCST90468712 | 10.55 |
| 699 | CXCL5/SDC4 ratio | GCST90314353 | 10.54 |
| 700 | Neutrophil percentage of white cells | GCST90002399 | 10.52 |
| 701 | CD84 levels | GCST90468653 | 10.52 |
| 702 | Leg fat-free mass (right) | Impedance measures | UKBB00000394 | 10.51 |
| 703 | Systolic blood pressure | GCST90301696 | 10.51 |
| 704 | Prostate cancer | GCST90274716 | 10.51 |
| 705 | Pain in limb | FING00001138 | 10.48 |
| 706 | ENO2/MGLL ratio | GCST90314663 | 10.48 |
| 707 | FXN/TRIAP1 ratio | GCST90314899 | 10.47 |
| 708 | MAP3K5/ZBTB16 ratio | GCST90315380 | 10.46 |
| 709 | IDP dMRI TBSS OD Pontine crossing tract | GCST90004403 | 10.46 |
| 710 | AARSD1/UBAC1 ratio | GCST90313135 | 10.45 |
| 711 | Leg predicted mass (right) | Impedance measures | UKBB00000397 | 10.43 |
| 712 | VSIG10 levels | GCST90471050 | 10.43 |
| 713 | FCAR levels | GCST90469197 | 10.43 |
| 714 | Takes medication for Diabetes/sugar? | GCST90475268 | 10.43 |
| 715 | EDAR/ERBIN ratio | GCST90314575 | 10.41 |
| 716 | Brain age gap | GCST90558034 | 10.40 |
| 717 | Fasciitis (PheCode 728.7) | GCST90476244 | 10.40 |
| 718 | Red blood cell (erythrocyte) distribution width | Blood count | UKBB00000748 | 10.40 |
| 719 | Arm predicted mass (right) | Impedance measures | UKBB00000050 | 10.39 |
| 720 | PAPPA levels | GCST90012036 | 10.38 |
| 721 | SH2D1A levels | GCST90470617 | 10.37 |
| 722 | DAG1/MGLL ratio | GCST90314377 | 10.36 |
| 723 | Spread type - Other type of spread/margarine | Diet | UKBB00000795 | 10.35 |
| 724 | Follicular lymphoma, hilmo (controls excluding all cancers) | FING00000548 | 10.34 |
| 725 | IDP dMRI TBSS ICVF Anterior corona radiata R | GCST90004349 | 10.33 |
| 726 | CXCL5 levels | GCST90468932 | 10.32 |
| 727 | REST UKBBICA NODEamps25 0014 | GCST90385497 | 10.31 |
| 728 | aparc-a2009s rh volume S-oc-middle+Lunatus | GCST90003055 | 10.31 |
| 729 | ICA1/TANK ratio | GCST90315112 | 10.30 |
| 730 | RETN/RNASET2 ratio | GCST90315768 | 10.28 |
| 731 | BMP6 levels | GCST90468454 | 10.28 |
| 732 | DAPP1/PMVK ratio | GCST90314396 | 10.27 |
| 733 | F9/RARRES2 ratio | GCST90314749 | 10.26 |
| 734 | CX3CL1 levels | GCST90274778 | 10.26 |
| 735 | All influenza | FING00000064 | 10.26 |
| 736 | FKBP5/MITD1 ratio | GCST90314844 | 10.25 |
| 737 | Usual walking pace | Physical activity | UKBB00000891 | 10.25 |
| 738 | SMAD1 levels | GCST90470675 | 10.24 |
| 739 | Forced vital capacity (FVC) | Spirometry | UKBB00000254 | 10.22 |
| 740 | Wegener granulomatosis | FING00001446 | 10.21 |
| 741 | Body mass index | GCST90428119 | 10.20 |
| 742 | Age completed full time education | Education | UKBB00000013 | 10.20 |
| 743 | Whole body water mass (UKB data field 23102) | GCST90468184 | 10.20 |
| 744 | PPCDC/RWDD1 ratio | GCST90315704 | 10.18 |
| 745 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T216 | ECGA000216 | 10.17 |
| 746 | NCK2/PLA2G4A ratio | GCST90315524 | 10.17 |
| 747 | Types of physical activity in last 4 weeks - Walking for pleasure (not as a means of transport) | Physical activity | UKBB00000875 | 10.17 |
| 748 | ESAM/JAM2 ratio | GCST90314712 | 10.16 |
| 749 | APP/DAG1 ratio | GCST90313320 | 10.15 |
| 750 | ATP5IF1/LYN ratio | GCST90313389 | 10.14 |
| 751 | SERPINE1 levels | GCST90470596 | 10.13 |
| 752 | ATP5IF1 levels | GCST90468392 | 10.13 |
| 753 | Time to complete round | Pairs matching | UKBB00000822 | 10.13 |
| 754 | HSIL lesion of the vulva | FING00000626 | 10.12 |
| 755 | PCDH17 levels | GCST90470169 | 10.12 |
| 756 | ATG4A/NSFL1C ratio | GCST90313368 | 10.10 |
| 757 | CD69/PPP1R2 ratio | GCST90313882 | 10.10 |
| 758 | CD300C/CLEC14A ratio | GCST90313786 | 10.09 |
| 759 | PCDH17/SEMA7A ratio | GCST90315605 | 10.09 |
| 760 | Ectopic pregnancy | FING00000487 | 10.08 |
| 761 | MAVS/RNF41 ratio | GCST90315395 | 10.06 |
| 762 | Fresh fruit consumption | GCST90132979 | 10.05 |
| 763 | ALDH1A1/CA3 ratio | GCST90313244 | 10.05 |
| 764 | Qualifications - CSEs or equivalent | Education | UKBB00000728 | 10.05 |
| 765 | Neuroticism | GCST003770 | 10.04 |
| 766 | EBAG9/TBCB ratio | GCST90314567 | 10.03 |
| 767 | Spicy food liking | GCST90094846 | 10.02 |
| 768 | Type 2 diabetes | GCST90468151 | 9.98 |
| 769 | DKK1/MGLL ratio | GCST90314473 | 9.98 |
| 770 | MPO levels | GCST90012031 | 9.98 |
| 771 | DNA methylation GrimAge acceleration | GCST90014288 | 9.97 |
| 772 | Left-hemisphere dorsal attention network to right-hemisphere control network white-matter structural connectivity | GCST90302699 | 9.97 |
| 773 | SUSD1/THPO ratio | GCST90315899 | 9.96 |
| 774 | Reticulocyte percentage (UKB data field 30240) | GCST90468101 | 9.95 |
| 775 | NUDC levels | GCST90470102 | 9.95 |
| 776 | Presence of other functional implants | Persons with potential health hazards related to family and personal history and certain conditions influencing health status | UKBB00000709 | 9.95 |
| 777 | OSCAR/TNFRSF14 ratio | GCST90315588 | 9.92 |
| 778 | AXL/GAS6 ratio | GCST90313419 | 9.92 |
| 779 | BCR/FOXO1 ratio | GCST90313490 | 9.90 |
| 780 | PCSK9 levels | GCST90428110 | 9.89 |
| 781 | Arthrosis | FING00000111 | 9.89 |
| 782 | RILP/RWDD1 ratio | GCST90315778 | 9.89 |
| 783 | Left-hemisphere somatomotor network to left-hemisphere control network white-matter structural connectivity | GCST90302673 | 9.89 |
| 784 | Diabetes diagnosed by doctor | Medical conditions | UKBB00000168 | 9.89 |
| 785 | Moderate to vigorous physical activity levels | GCST006097 | 9.87 |
| 786 | COL18A1/RETN ratio | GCST90314170 | 9.86 |
| 787 | TREML1 levels | GCST90470961 | 9.86 |
| 788 | CSTB levels | GCST90468898 | 9.84 |
| 789 | Vascular/heart problems diagnosed by doctor - None of the above | Medical conditions | UKBB00000899 | 9.84 |
| 790 | Lesion of plantar nerve | FING00000720 | 9.83 |
| 791 | ANGPT1/MPIG6B ratio | GCST90313265 | 9.82 |
| 792 | Arm fat-free mass (right) | Impedance measures | UKBB00000048 | 9.81 |
| 793 | Medication for pain relief, constipation, heartburn - None of the above | Medication | UKBB00000457 | 9.81 |
| 794 | Alcohol drinker status - Current | Alcohol | UKBB00000021 | 9.81 |
| 795 | CD79B/FCRL1 ratio | GCST90313899 | 9.78 |
| 796 | SDC4/WWP2 ratio | GCST90315821 | 9.78 |
| 797 | Disorders of synovium and tendon | FING00000462 | 9.78 |
| 798 | LGALS8/SOD2 ratio | GCST90315320 | 9.78 |
| 799 | SNAP23/SNAP29 ratio | GCST90315855 | 9.77 |
| 800 | AXIN1/NFATC1 ratio | GCST90313415 | 9.77 |
| 801 | Multi-site chronic pain | Other trait | UKBB00000490 | 9.77 |
| 802 | Coffee intake (standard GWA) | GCST90267274 | 9.76 |
| 803 | Sleep disorders (combined) | FING00001311 | 9.76 |
| 804 | Omega-3 fatty acids to total fatty acids percentage | GCST90502460 | 9.74 |
| 805 | CASP2 levels | GCST90468544 | 9.73 |
| 806 | Medication use (drugs used in diabetes) | GCST90018761 | 9.73 |
| 807 | Arm predicted mass (left) | Impedance measures | UKBB00000049 | 9.72 |
| 808 | PDGFA/PRSS27 ratio | GCST90315616 | 9.72 |
| 809 | POSTN levels | GCST90470288 | 9.72 |
| 810 | AZU1/MPO ratio | GCST90313425 | 9.70 |
| 811 | Qualifications - Other professional qualifications eg: nursing, teaching | Education | UKBB00000732 | 9.70 |
| 812 | lymphocyte (fraction, minimum, inv-norm transformed) | GCST90475438 | 9.70 |
| 813 | SNAP25 levels | GCST90470691 | 9.68 |
| 814 | Forced expiratory volume (baseline) | GCST90565844 | 9.67 |
| 815 | PRTN3 levels | GCST90470348 | 9.67 |
| 816 | Sleeplessness / insomnia | Sleep | UKBB00000778 | 9.65 |
| 817 | Plasma cystathionine levels in chronic kidney disease | GCST90264974 | 9.65 |
| 818 | EGLN1/PSIP1 ratio | GCST90314620 | 9.65 |
| 819 | Arm fat-free mass (left) | Impedance measures | UKBB00000047 | 9.64 |
| 820 | Colitis, primary sclerosing, strict definition | FING00000313 | 9.63 |
| 821 | Illnesses of father - High blood pressure | Family history | UKBB00000343 | 9.62 |
| 822 | Hemoglobin A1c (HbA1c, maximum, inv-norm transformed) | GCST90475091 | 9.62 |
| 823 | KIRREL2/PLA2G1B ratio | GCST90315251 | 9.61 |
| 824 | Insulin pump user (PheCode 250.3) | GCST90475680 | 9.61 |
| 825 | Alcohol usually taken with meals | Alcohol | UKBB00000025 | 9.61 |
| 826 | Hemoglobin A1c (HbA1c, mean, inv-norm transformed) | GCST90475094 | 9.58 |
| 827 | Leg fat percentage (right) | Impedance measures | UKBB00000392 | 9.58 |
| 828 | MANSC1/PODXL2 ratio | GCST90315371 | 9.58 |
| 829 | Leisure/social activities - Other group activity | Social support | UKBB00000400 | 9.57 |
| 830 | EPO/TFRC ratio | GCST90314684 | 9.57 |
| 831 | NUDT5/SERPINB1 ratio | GCST90315581 | 9.55 |
| 832 | Neutrophill percentage (UKB data field 30200) | GCST90468093 | 9.55 |
| 833 | CTSO levels | GCST90179277 | 9.53 |
| 834 | Phosphatidylinositol-O_36:0_[M-H]1- levels | GCST90060480 | 9.52 |
| 835 | Monocyte percentage | Blood count | UKBB00000480 | 9.52 |
| 836 | ARHGAP1/SPARC ratio | GCST90313344 | 9.52 |
| 837 | SERPINE1/USP8 ratio | GCST90315835 | 9.51 |
| 838 | Mean corpuscular hemoglobin concentration | GCST90002391 | 9.50 |
| 839 | RGMA/RGMB ratio | GCST90315769 | 9.50 |
| 840 | Spondyloarthritis | FING00001323 | 9.49 |
| 841 | BCAN/NCAN ratio | GCST90313481 | 9.49 |
| 842 | CNTN2 levels | GCST90468804 | 9.48 |
| 843 | Systolic blood pressure (BMI adjusted) | GCST90335163 | 9.48 |
| 844 | Exposure to tobacco smoke outside home | Smoking | UKBB00000229 | 9.47 |
| 845 | Cardiometabolic multimorbidity | GCST90274723 | 9.47 |
| 846 | PF4 levels | GCST90470211 | 9.47 |
| 847 | Operative procedures - Insertion of prosthetic replacement for lens NEC | Summary Operations | UKBB00000583 | 9.46 |
| 848 | ITGB1BP2/USP8 ratio | GCST90315223 | 9.45 |
| 849 | Radiculopathy | FING00001238 | 9.45 |
| 850 | ITGB1BP2/WASF1 ratio | GCST90315224 | 9.45 |
| 851 | EPPK1 levels | GCST90469137 | 9.44 |
| 852 | Arthropathy in ulcerative colitis | FING00000110 | 9.44 |
| 853 | F2R levels | GCST90469168 | 9.44 |
| 854 | sodium (minimum, inv-norm transformed) | GCST90476397 | 9.43 |
| 855 | Volume of right medial nucleus | GCST90475042 | 9.43 |
| 856 | Benign neoplasm: Choroid | FING00000170 | 9.42 |
| 857 | IL6ST/MARCO ratio | GCST90315167 | 9.42 |
| 858 | DBI/EDAR ratio | GCST90314408 | 9.41 |
| 859 | RAP1A levels | GCST90470425 | 9.41 |
| 860 | Type 1 diabetes (PheCode 250.1) | GCST90475661 | 9.41 |
| 861 | TNFRSF1A levels | GCST90012015 | 9.41 |
| 862 | ATP5IF1/F2R ratio | GCST90313384 | 9.40 |
| 863 | CEACAM8/PGLYRP1 ratio | GCST90314003 | 9.40 |
| 864 | Alcohol use and misuse (confirmatory factor analysis Factor 22) | GCST90309356 | 9.39 |
| 865 | GOLM2 levels | GCST90469376 | 9.37 |
| 866 | Esophagitis, GERD and related diseases (PheCode 530.1) | GCST90476046 | 9.36 |
| 867 | CA3 levels | GCST90468512 | 9.36 |
| 868 | IDP dMRI ProbtrackX OD fma | GCST90004460 | 9.35 |
| 869 | IDP dMRI TBSS ICVF Uncinate fasciculus R | GCST90004371 | 9.34 |
| 870 | Sciatica+with lumbago | FING00001279 | 9.34 |
| 871 | SERPINI1 levels | GCST90470602 | 9.34 |
| 872 | Non-cancer illness code, self-reported - osteoarthritis | Medical conditions | UKBB00000521 | 9.34 |
| 873 | IRAK1/NFATC1 ratio | GCST90315194 | 9.33 |
| 874 | Principal component-derived dietary pattern 1 | GCST90133006 | 9.33 |
| 875 | TMSB10/TXNRD1 ratio | GCST90315925 | 9.29 |
| 876 | aparc-Desikan lh area fusiform | GCST90003079 | 9.29 |
| 877 | CASP3/LYN ratio | GCST90313635 | 9.29 |
| 878 | ABHD14B/APRT ratio | GCST90313137 | 9.28 |
| 879 | Lamb liking | GCST90094790 | 9.28 |
| 880 | Enthesopathies of lower limb, excluding foot | FING00000509 | 9.28 |
| 881 | DNPH1/PDGFB ratio | GCST90314527 | 9.27 |
| 882 | CD79B levels | GCST90468648 | 9.27 |
| 883 | CLEC1B levels | GCST90468768 | 9.27 |
| 884 | Obesity due to excess calories | FING00000896 | 9.27 |
| 885 | SSC5D levels | GCST90470748 | 9.27 |
| 886 | SMAD3 levels | GCST90470677 | 9.26 |
| 887 | Leg fat percentage (left) | Impedance measures | UKBB00000391 | 9.25 |
| 888 | Mean platelet volume at delivery | GCST90302232 | 9.23 |
| 889 | Treatment speciality of consultant (recoded) - General medicine | Summary Administration | UKBB00000832 | 9.23 |
| 890 | Diseases of male genital organs | FING00000426 | 9.22 |
| 891 | Potassium in urine | Urine assays | UKBB00000655 | 9.22 |
| 892 | Basal metabolic rate | Impedance measures | UKBB00000086 | 9.20 |
| 893 | Symptoms concerning nutrition, metabolism, and development (PheCode 1002) | GCST90475556 | 9.20 |
| 894 | Arm fat percentage right (UKB data field 23119) | GCST90468158 | 9.20 |
| 895 | Hypo-osmolality and hyponatraemia | FING00000648 | 9.19 |
| 896 | Hip circumference | Body size measures | UKBB00000328 | 9.18 |
| 897 | Thyroid stimulating hormone levels within normal range in pregnancy | GCST90435195 | 9.17 |
| 898 | Other anxiety disorders | FING00000960 | 9.17 |
| 899 | LAT2 levels | GCST90469739 | 9.17 |
| 900 | Methods of admission to hospital (recoded) - Emergency admission: A&E | Summary Administration | UKBB00000464 | 9.17 |
| 901 | F-lentils/beans liking (derived food-liking factor) | GCST90094793 | 9.17 |
| 902 | DARS1 levels | GCST90468947 | 9.16 |
| 903 | ATP5IF1/FXN ratio | GCST90313386 | 9.16 |
| 904 | Father's age at death | Family history | UKBB00000241 | 9.15 |
| 905 | IDP dMRI TBSS OD Genu of corpus callosum | GCST90004404 | 9.14 |
| 906 | GZMB/IL15 ratio | GCST90315015 | 9.13 |
| 907 | Arm fat percentage left (UKB data field 23123) | GCST90468157 | 9.12 |
| 908 | APRT/PSME1 ratio | GCST90313338 | 9.11 |
| 909 | Plasma 3-hydroxybutyroylglycine** levels in chronic kidney disease | GCST90264488 | 9.10 |
| 910 | SPRY2 levels | GCST90470738 | 9.09 |
| 911 | PDGFA/USP8 ratio | GCST90315621 | 9.08 |
| 912 | Red cell distribution width | GCST90002404 | 9.08 |
| 913 | CNST/ITGB1BP2 ratio | GCST90314158 | 9.08 |
| 914 | lymphocyte (fraction, mean, inv-norm transformed) | GCST90475435 | 9.08 |
| 915 | ENO1 levels | GCST90469109 | 9.07 |
| 916 | Blood cell traits latent factor 22 (white cell) | GCST90559264 | 9.07 |
| 917 | CST3/RETN ratio | GCST90314297 | 9.05 |
| 918 | SCARF1/TNFRSF14 ratio | GCST90315812 | 9.04 |
| 919 | IPCEF1 levels | GCST90469624 | 9.03 |
| 920 | TRIM5 levels | GCST90470970 | 9.01 |
| 921 | Other peripheral nerve disorders (PheCode 351) | GCST90475842 | 9.01 |
| 922 | IGSF8/VSIR ratio | GCST90315141 | 9.00 |
| 923 | Basophil count variance | GCST90565682 | 9.00 |
| 924 | Hip circumference (UKB data field 49) | GCST90468170 | 8.99 |
| 925 | Hand grip strength (left) | Hand grip strength | UKBB00000300 | 8.99 |
| 926 | Reticulocyte fraction of red cells | GCST90002406 | 8.95 |
| 927 | Forced expiratory volume in 1-second (FEV1) | Spirometry | UKBB00000251 | 8.95 |
| 928 | Lymphocyte percentage of white cells | GCST004632 | 8.94 |
| 929 | IPCEF1/SERPINE1 ratio | GCST90315184 | 8.94 |
| 930 | aparc-a2009s rh thickness G-temporal-middle | GCST90003714 | 8.92 |
| 931 | DARS1/MAP4K5 ratio | GCST90314404 | 8.91 |
| 932 | BACH1/NFATC1 ratio | GCST90313444 | 8.89 |
| 933 | Left-hemisphere salience/ventral attention network to right-hemisphere default mode network white-matter structural connectivity | GCST90302718 | 8.88 |
| 934 | Current Smoker | FING00000371 | 8.88 |
| 935 | Mild obesity-related type 2 diabetes | GCST90026415 | 8.87 |
| 936 | aseg lh volume Caudate | GCST90002621 | 8.87 |
| 937 | Fluid intelligence score decline (difference score) | GCST90565862 | 8.86 |
| 938 | CLEC1B/GP1BA ratio | GCST90314091 | 8.86 |
| 939 | Cataract (PheCode 366) | GCST90043785 | 8.86 |
| 940 | Glucose levels | GCST90092819 | 8.85 |
| 941 | ADGRF5 levels | GCST90468239 | 8.85 |
| 942 | Prescriptions - doxazosin | alpha1-antagonist,alpha blocker | UKBB00000679 | 8.85 |
| 943 | IDP dMRI TBSS ISOVF Fornix | GCST90004482 | 8.85 |
| 944 | DDAH1 levels | GCST90468966 | 8.84 |
| 945 | Right-hemisphere somatomotor network to right-hemisphere default mode network white-matter structural connectivity | GCST90302793 | 8.84 |
| 946 | Coffee type: Decaffeinated coffee (any type) (UKB data field 1508_1) | GCST90132974 | 8.84 |
| 947 | Sum eosinophil basophil counts | GCST004624 | 8.83 |
| 948 | Diffuse idiopathic skeletal hyperostosis flow score | GCST90134532 | 8.83 |
| 949 | BA-exvivo rh area BA45 | GCST90003229 | 8.82 |
| 950 | Monocyte count (UKB data field 30130) | GCST90468090 | 8.82 |
| 951 | Mother's age | Family history | UKBB00000484 | 8.82 |
| 952 | PDGFB levels | GCST90470189 | 8.82 |
| 953 | Left-hemisphere salience/ventral attention network to pallidum white-matter structural connectivity | GCST90302722 | 8.81 |
| 954 | White blood cell count | GCST90002374 | 8.81 |
| 955 | High light scatter reticulocyte percentage (UKB data field 30290) | GCST90468077 | 8.81 |
| 956 | Sum neutrophil eosinophil counts | GCST004613 | 8.80 |
| 957 | Type 2 diabetes | GCST010118 | 8.80 |
| 958 | ALOX15B levels | GCST90617547 | 8.80 |
| 959 | Granulocyte count | GCST004614 | 8.80 |
| 960 | monocyte (fraction, maximum, inv-norm transformed) | GCST90475508 | 8.79 |
| 961 | CLEC1B/PPP1R2 ratio | GCST90314101 | 8.78 |
| 962 | CLEC1B/LBR ratio | GCST90314095 | 8.77 |
| 963 | TIMP3 levels | GCST90470871 | 8.74 |
| 964 | monocyte (fraction, mean, inv-norm transformed) | GCST90475511 | 8.74 |
| 965 | Coffee type: Ground coffee (include espresso, filter etc) (UKB data field 1508_3) | GCST90041803 | 8.74 |
| 966 | PDAP1 levels | GCST90470179 | 8.73 |
| 967 | TNFRSF13C levels | GCST90470906 | 8.73 |
| 968 | SULT1A1 levels | GCST90470781 | 8.70 |
| 969 | Fluid intelligence score decline (log-difference score) | GCST90565852 | 8.70 |
| 970 | PDCD1/TNFRSF4 ratio | GCST90315609 | 8.70 |
| 971 | Type 2 diabetes | GCST90018706 | 8.70 |
| 972 | Vegetables liking | GCST90094862 | 8.70 |
| 973 | PLIN3/VSIR ratio | GCST90315679 | 8.70 |
| 974 | SDC4/SMAD1 ratio | GCST90315820 | 8.70 |
| 975 | SERPINH1 levels | GCST90470601 | 8.69 |
| 976 | Hereditary ataxia | FING00000610 | 8.69 |
| 977 | Red blood cell erythrocyte distribution width (UKB data field 30070) | GCST90468099 | 8.69 |
| 978 | PEAR1/SCARF1 ratio | GCST90315642 | 8.68 |
| 979 | BCR/ICA1 ratio | GCST90313493 | 8.68 |
| 980 | Age-related eyesight deterioration (confirmatory factor analysis Factor 27) | GCST90309361 | 8.68 |
| 981 | Neutrophill percentage | Blood count | UKBB00000498 | 8.67 |
| 982 | TFPI2 levels | GCST90470838 | 8.67 |
| 983 | KIFBP/LYN ratio | GCST90315246 | 8.67 |
| 984 | DKK1/VTA1 ratio | GCST90314485 | 8.66 |
| 985 | ANXA3/BID ratio | GCST90313279 | 8.65 |
| 986 | Ankylosing spondylitis | FING00000089 | 8.65 |
| 987 | S100A11/S100A12 ratio | GCST90315798 | 8.64 |
| 988 | PPP1R12A/VEGFC ratio | GCST90315715 | 8.64 |
| 989 | F8 levels | GCST90240725 | 8.63 |
| 990 | IDP dMRI TBSS MD Posterior thalamic radiation R | GCST90004055 | 8.63 |
| 991 | Sum basophil neutrophil counts | GCST004620 | 8.62 |
| 992 | Mean time to correctly identify matches | Reaction time | UKBB00000453 | 8.62 |
| 993 | Ever highly irritable/argumentative for 2 days | Mental health | UKBB00000219 | 8.62 |
| 994 | DBNL/EDAR ratio | GCST90314416 | 8.61 |
| 995 | GHRL levels | GCST90469341 | 8.60 |
| 996 | aseg global volume 3rd-Ventricle | GCST90002599 | 8.59 |
| 997 | LAT/PDGFA ratio | GCST90315285 | 8.59 |
| 998 | METAP1D/PLXNA4 ratio | GCST90315427 | 8.58 |
| 999 | Glucose (fasting status unknown, maximum, inv-norm transformed) | GCST90475329 | 8.58 |
| 1000 | IPCEF1/TBCB ratio | GCST90315187 | 8.57 |